Catalyst Wire Dossier Catalyst Wire Dossier

REGN17372

· Regeneron Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REGN17372, covering 2026-04-15 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

See pricing